Qral Group competitors

Clive Richardson is a Board Member at Akari Therapeutics PLC. He has worked as Head:Operations at Volution Immuno Pharmaceuticals SA, Board Member at CLINISYS SOLUTIONS LIMITED, and Interim CEO/COO at Akari Therapeutics PLC. Clive works or has worked as Head:Equities Research at Investec. He attended Trinity College Oxford.

Randall B. Riggs is a Chief Executive Officer and President at ADVANCED CANCER THERAPEUTICS.

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

Serial entrepreneur with three decades of experience in the biopharmaceutical industry including roles within established and emerging companies as well as an active consulting practice. Proven track record of results throughout a company’s lifecycle including company formation, fundraising, recruiting and retention of teams, execution of operating plans and business development.

Bill Martin is a Chief Executive Officer at BlackThorn Therapeutics. He has experience at Merck & Co. Inc. and has worked as Head:Research Portfolio Planning at THERAVANCE, President/COO/Co-founder at BlackThorn Therapeutics, and Chief Scientific Officer at BlackThorn Therapeutics. Bill studied at Brown University and Swarthmore College.